DeepVerge has announced breakthrough interim analysis that demonstrates its ability to host the SARS-CoV-2 virus on Labskin-cloned human skin microbiome.
This is highly significant in the respect that to date society has been forced to depend on anecdotal or theoretical evidence (from the World Health Organization (‘the WHO’) and various health agencies) to determine how infectious skin is, as humans touch different surfaces and each other.
The body of research, protocols and methods now created on Labskin while utilising the real coronavirus, offers formal confirmation and sets necessary standards for oversight testing across a broad range of sanitisers, skin and health care products.
The study is now being extended to further investigate behaviours of COVID-19 on skin and enable testing on anti-viral and dental products. Assuming its successful completion, this could rapidly and economically provide scientific evidence that formally backs-up any product claims to kill or address risk of transmission of the virus (or its mutations) without first having to expose human volunteers to it through clinical trials.
We would draw your attention to the various disclaimers in the document both at the beginning and at the end of the note. Retail clients (as defined by the rules of the FCA) must not rely on the research document. In particular you should note that the research document is a non-independent marketing communication. The analyst who has prepared the research is aware that TPI provides research to DeepVerge plc. Accordingly the research has not been prepared in accordance with legal requirements designed to promote the independence of investment research and is not subject to any prohibitions on dealing ahead of its dissemination.
The information in the document is published solely for information purposes and is not to be construed as a solicitation or an offer to buy or sell any securities or related financial instruments. The material contained in the document is general information intended for recipients who understand the risks associated with equity investment in smaller companies. It does not constitute a personal recommendation as defined by the FCA or take into account the particular investment objectives, financial situation or needs of individual investors nor provide any indication as to whether an investment, a course of action or the associated risks are suitable for the recipient.
Copyright © 2019 Turner Pope Investments (TPI) Limited, all rights reserved.
